Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.
Objective: To investigate the efficacy of safinamide, compared to placebo, as add-on therapy to stable doses of levodopa, on both motor and non-motor symptoms in…The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments
Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…Real-world non-motor score changes in Parkinson’s disease patients with motor fluctuations: The J-FIRST study
Objective: To identify changes in non-motor symptoms (NMSs) over time in Japanese Parkinson’s disease (PD) patients without dementia exhibiting motor fluctuations. Background: PD can cause…Perceptions of Fluctuation Treatment in Parkinson’s Disease Impact Suicidality
Objective: Our goal was to examine the relationship between suicidality and motor fluctuations in Parkinson’s disease (PD) patients. Background: On/off motor fluctuations in PD are…Automated assessment of advanced motor Parkinson’s disease; a pilot study of the Parkinson’s KinetiGraph as an objective tool for measurement of motor fluctuations
Objective: To evaluate the utility of the Parkinson's KinetiGraph (PKG) as a tool in advanced Parkinson's disease (PD) to determine need for treatment change by…Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I
Objective: Evaluate the safety of opicapone (OPC) in Parkinson's disease patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background: OPC,…Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease
Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana
Objective: To prospectively investigate the response to acute levodopa challenge in patients with advanced Parkinson's disease (PD) never treated before. Background: Pathophysiological mechanisms underlying motor…Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: Exploratory by-week efficacy analysis of pooled phase III studies
Objective: Evaluate the onset and stability of the therapeutic effect of opicapone (OPC) compared to placebo in patients with Parkinson's disease and motor fluctuations over…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- Next Page »